Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma.
about
Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.How we manage autologous stem cell transplantation for patients with multiple myelomaPredicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected.Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma.Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myelomaHematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma.Optimizing Stem Cells Mobilization Strategies to Ameliorate Patient Outcomes: A Review of Guide- lines and Recommendations.Identification of the CD34 enumeration on the day before stem cell harvest that best predicts poor mobilization.Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.Novel mobilization strategies to enhance autologous immune effector cells in multiple myeloma.Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-fEfficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen.Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean.Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation
P2860
Q33408698-2E99A803-F09E-43B8-B2B8-65BB35335A08Q34019581-AF33374B-3300-4133-B2FC-64E32CF58171Q34490998-8FE87B2B-713D-4361-B113-50F76EDF18C7Q34971081-73A9B3E1-332A-434A-BF58-AC15CE312BE7Q35760079-5194C9D0-A25A-4AB5-9DB1-58FE3F1ADC3BQ35911212-E9A5E90C-722B-4B69-ACD0-A7CDEE07A662Q36428104-ECB1119B-6237-49EE-BC6F-1245C6070791Q36541807-29FC40DD-9D8B-4774-8750-735993D42C9FQ37313790-F313500E-C6BE-421A-8D2A-7AFF245812CCQ37429206-40B23000-6CC7-4D5A-9924-7772E5666BFBQ37432037-8E0527FA-B4AD-4372-988E-239D839B8496Q37682128-5FE7D4A4-A3C9-42AB-BE0D-E8320BA1B36CQ37851155-235C4E3E-8AE2-4DC4-A343-FEA9D7ACC1D9Q38160461-59CB5D0F-D096-4D19-9C53-CF04C452C63BQ38176669-C3CA5673-6D46-48D7-9D78-7F128130D79EQ38200909-ADCCD317-9CAA-48C0-BAD9-817EE02709A9Q39066209-3A64E95E-C11B-466F-B2AB-3673F9C0F862Q39534253-563F7966-8ED4-42C1-B802-3329E1FEEDE5Q41003137-533A2CA7-1E25-43F2-82F8-36E9490CBD3BQ41267193-94F614E0-517A-46CE-94D0-21F39E744D89Q41274044-CB448187-10F6-4548-B0BB-291350EAF999Q41694417-880D6FB1-A86B-43A0-9515-512073A42DDBQ44556507-ECD5CE97-D8F8-4D27-AA7A-9CE833BC15B7Q45735258-141B15B3-AE2B-4EA0-94D1-B3932CCE0DFFQ45892382-EE30A17C-F12B-40B7-8BFF-9D32D1CA780DQ50703524-958D728C-4F20-4902-9CA3-ED90A76B070EQ51405815-66E7C7A8-1569-4F8D-AAAD-DB17F4B34FB4Q51680781-08FDB0D2-C4F5-4C81-A30D-E3255587B54AQ51705517-636D4F58-02A0-447B-895B-F63CC0EEBDE8Q52919426-00262556-415E-4D09-94D5-3CE61179945BQ53130499-B66E7BAB-5F1D-4052-8F70-0F221FAB87E3Q53262189-79BA8A22-F8FA-422E-88BB-130815990C53Q53350065-0DCFDDDA-7594-418C-BCB1-882034FCDB43Q53922357-F371DA63-BBE1-4189-8549-5108D0FF6FA2Q57903940-B1A717FE-FC6F-4E40-A20A-EFE71AFC9DBE
P2860
Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Comparison of high-dose CY and ...... atients with multiple myeloma.
@ast
Comparison of high-dose CY and ...... atients with multiple myeloma.
@en
Comparison of high-dose CY and ...... atients with multiple myeloma.
@nl
type
label
Comparison of high-dose CY and ...... atients with multiple myeloma.
@ast
Comparison of high-dose CY and ...... atients with multiple myeloma.
@en
Comparison of high-dose CY and ...... atients with multiple myeloma.
@nl
prefLabel
Comparison of high-dose CY and ...... atients with multiple myeloma.
@ast
Comparison of high-dose CY and ...... atients with multiple myeloma.
@en
Comparison of high-dose CY and ...... atients with multiple myeloma.
@nl
P2093
P2860
P356
P1476
Comparison of high-dose CY and ...... atients with multiple myeloma.
@en
P2093
A Dispenzieri
D A Gastineau
J L Winters
M R Litzow
S R Hayman
P2860
P2888
P304
P356
10.1038/BMT.2008.369
P407
P577
2008-11-10T00:00:00Z
P5875
P6179
1043142231